Guest
Guest
Jan 30, 2026
1:46 AM
|
Vriligy 60?mg contains dapoxetine, a short?acting selective serotonin reuptake inhibitor (SSRI) taken on demand to treat premature ejaculation (PE). Its “success rate” isn’t reported as a single fixed number, but clinical studies provide good evidence of how effective a 60?mg dose can be in real?world outcomes compared with lower doses or placebo. Clinical Efficacy Highlights General effectiveness in PE: Dapoxetine 60?mg has been evaluated in multiple large randomized clinical trials involving thousands of men. These studies consistently Vriligy 60mg that 60?mg significantly improves ejaculatory control, intravaginal ejaculatory latency time (IELT), and sexual satisfaction compared with placebo and often more than the 30?mg dose. Effectiveness rates observed: In one multicenter study, dapoxetine (30?mg or 60?mg) showed an overall effectiveness rate of ~83% within approved doses; specifically, the 60?mg dose helped 55.7% of men who did not respond to 30?mg reach clinically meaningful benefit. Other pooled analyses show significant increases in IELT with 60?mg versus lower doses — meaning many men stay in control for longer. Response in patient?reported outcomes: In trials, a greater proportion of men on 60?mg reported improved ejaculatory control and sexual satisfaction compared with placebo. For example, user?defined “good control” percentages were higher with 60?mg than with 30?mg or placebo.
|
